Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Matinas BioPharma Holdings, Inc.MTNB · Entity 8443 | Chief Scientific Officer | December 14, 2021 | December 15, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Matinas BioPharma Holdings, Inc.
Report date December 14, 2021 · Filed December 15, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.92 · Expires 2031-12-13 | Direct | 275,000 |
Reported balance
After 2021-12-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-12-14 · Grant · Acquired 275,000 · Balance 275,000 F1: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 14, 2021 Filed Dec 15, 2021 21:22 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock Option (right to Buy) · Derivative | 275,000 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0000905718-21-001609 · matinas_fm4dec152021.xml · derivative · entry 1 MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2031-12-13 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on December 14, 2022 with the remaining shares to vest in equal monthly installments on the last day of each month over a period of 36 months commencing December 31, 2022. Read SEC document |
| September 03, 2021 Filed Sep 14, 2021 17:30 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherCommon Stock, par value $0.0001 per share | 462,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-022716 · ownership.xml · nonDerivative · entry 1 MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,919,715 F1 · kind: Shares received pursuant to an amendment to the Agreement and Plan of Merger dated as of January 29, 2015 by an among the Issuer, Saffron Merger Sub, Inc. and Aquarius Biotechnologies Inc. Read SEC document |
| June 19, 2021 Filed Jun 24, 2021 17:35 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | ConversionSeries B Preferred Stock · Derivative | 10 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0000905718-21-000822 · matinasbio_fm4jun192021.xml · derivative · entry 3 MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date. Read SEC document |
| June 19, 2021 Filed Jun 24, 2021 17:35 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | ConversionCommon Stock, par value $0.0001 per share | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-000822 · matinasbio_fm4jun192021.xml · nonDerivative · entry 2 MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,457,565 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date. Read SEC document |
| June 19, 2021 Filed Jun 24, 2021 17:35 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherCommon Stock, par value $0.0001 per share | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-000822 · matinasbio_fm4jun192021.xml · nonDerivative · entry 1 MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,437,565 F1 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock. Read SEC document |
| January 01, 2021 Filed Jan 4, 2021 18:30 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $1.36 | $0.00 |
DisclosureSEC source: 0001493152-21-000135 · ownership.xml · derivative · entry 1 MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-12-31 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2022 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2022. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 21:00 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherCommon Stock, par value $0.0001 per share | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-011760 · ownership.xml · nonDerivative · entry 1 MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,429,565 F1 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 300 shares of Common Stock for each share of Series B Preferred Stock. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 17:30 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001493152-20-011534 · ownership.xml · derivative · entry 1 MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-06-16 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. Vesting is performance based and tied to achievement of positive topline ENHANCE-IT data (the "Milestone"). The option vests as to 1/3 upon achievement of the Milestone, with the remaining options to vest 1/3 on the first anniversary of such Milestone and 1/3 on the second anniversary of such Milestone. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 16:06 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 100,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0001493152-20-000125 · ownership.xml · derivative · entry 2 MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-01-01 F2 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan. The option vests as to 25% of the shares on January 1, 2021 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on February 1, 2021. Read SEC document |
| June 21, 2019 Filed Jan 3, 2020 16:06 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherCommon Stock, par value $0.0001 per share | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-000125 · ownership.xml · nonDerivative · entry 1 MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,426,565 F1 · kind: Stock dividend, payable to all holders of records of Series B Preferred Stock of 200 shares of Common Stock for each share of Series B Preferred Stock. Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 18:35 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.08 | $0.00 |
DisclosureSEC source: 0000905718-19-000108 · mannino-matinasfm4_feb112019.xml · derivative · entry 1 MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2029-02-10 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests as to 25% of the shares on February 11, 2020 with the remaining shares to vest in equal monthly installments over a period of 36 months commencing on March 1, 2020. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 16:40 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseSeries B Convertible Preferred Stock · Derivative | 10 | $1,000.00 Strike: $0.50 | $10,000.00 |
DisclosureSEC source: 0000905718-18-000590 · mannino-matinasfm4_jun212018.xml · derivative · entry 1 MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_date: On June 21, 2018, the Reporting Person purchased 10 shares of Series B Convertible Preferred Stock from the Issuer in a public offering. Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. F1 · derivative.expiration_date: On June 21, 2018, the Reporting Person purchased 10 shares of Series B Convertible Preferred Stock from the Issuer in a public offering. Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. Read SEC document |
| April 30, 2018 Filed May 2, 2018 17:15 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0000905718-18-000452 · matinasbiopfm4_apr302018.xml · derivative · entry 1 MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · Not disclosed shares Expires 2028-04-29 F1 · derivative.exercise_date: 25% of the shares vest on April 30, 2019 and the remaining shares vest in equal monthly installments over the next 36 months. Read SEC document |
| September 11, 2017 Filed Sep 15, 2017 16:18 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseCommon Stock | 5,000 | $1.41 | $7,050.00 |
DisclosureSEC source: 0000905718-17-000833 · mannino_fm4sept112017.xml · nonDerivative · entry 1 MANNINO RAPHAEL J · CIK 0001196697 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,424,565 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.